Skip to main content

Table 1 Demographic characteristics of primary LC patients with or without t-AML

From: Clinicopathological features, risk and survival in lung cancer survivors with therapy-related acute myeloid leukaemia

Variables, No. (%) With t-AML
(N = 104)
Without t-AML
(N = 158,541)
P
Sex    0.087
 Male 52 (50) 92,390 (58.3)  
 Female 52 (50) 66,151 (41.7)  
Race    0.999
 White 86 (82.7) 130,695 (82.4)  
 Black 11 (10.6) 16,891 (10.7)  
 Other 7 (6.7) 10,824 (6.8)  
Age of LC diagnosis, median (range) 62.5 (41–82) 64 (10–100) 0.332
 < 65 years 58 (55.8) 80,876 (51.0)  
 ≥ 65 years 46 (44.2) 77,665 (49.0)  
Period of diagnosis    0.131
 1975–1984 7 (6.7) 22,500 (14.2)  
 1985–1994 12 (11.5) 33,044 (20.8)  
 1995–2004 29 (27.9) 45,654 (28.8)  
 2005–2015 56 (53.8) 57,342 (36.2)  
Surgical treatment    0.006
 Yes 22 (21.2) 19,395 (12.2)  
 No 82 (78.8) 139,146 (87.8)  
Radiation treatment    0.001
 Yes 78 (75.0) 92,389 (58.3)  
 No/unknown 26 (25.0) 66,152 (41.7)  
Stage    < 0.001
 Localized/regional 53 (51.0) 41,086 (25.9)  
 Distant 39 (37.5) 81,744 (52.2)  
 Unknown 12 (11.5) 34,711 (21.9)  
Pathologic grade    0.659
 I or II 13 (12.5) 16,116 (10.2)  
 III or IV 39 (37.5) 64,510 (40.7)  
 Unknown 52 (50.0) 77,915 (49.1)  
Histologic type    0.09
 SCLC 42 (40.4) 51,078 (32.2)  
 NSCLC 59 (56.7) 96,664 (61.0)  
 Unknown 3 (2.9) 10,799 (6.8)  
  1. LC Lung cancer, t-AML Therapy-related acute myeloid leukaemia, NSCLC Non-small cell lung cancer, SCLC Small cell lung cancer, SEER Surveillance, Epidemiology, and End Results
\